IP Library Granted Patent US 12662663
Granted Patent B2
US 12662663 · App. 17/926,208 · Granted Jun 23, 2026

Use of a deficient fusion protein for nuclease activity so as to induce meiotic recombinations

Inventors: Alexandre Serero (Colombes, FR); Alain Nicolas (Paris, FR)
Assignees: MEIOGENIX; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; SORBONNE UNIVERSITE
C12N9/22C12N9/90C12N15/63C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662663
App. No.
17/926,208
Granted
Jun 23, 2026
Kind
B2
Abstract

The present invention relates to a fusion protein comprising a domain of a nuclease from the class II CRISPR system, and a Spoll domain, wherein both domains of the fusion protein have deficient nuclease activity, as well as the use of this protein to induce targeted meiotic recombinations in a eukaryotic cell.

Claims (45)

1 . A fusion protein, or a nucleic acid encoding the fusion protein, wherein the fusion protein comprises:

(i) a class II type II CRISPR nuclease that has deficient nuclease activity as compared to a wild-type class II type II nuclease; and

(ii) a Spo11 protein that has deficient nuclease activity as compared to a wild-type Spo11 protein.

2 . The fusion protein of claim 1 , wherein the class II type II nuclease is a Cas9 nuclease.

3 . The fusion protein of claim 1 , wherein the class II type II nuclease comprises a polypeptide sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43.

4 . The fusion protein of claim 3 , wherein the polypeptide sequence comprises an amino acid substitution at a position corresponding to D10 in SEQ ID NO: 38 and/or an amino acid substitution at a position corresponding to H840 in SEQ ID NO: 38.

5 . The fusion protein of claim 4 , wherein the amino acid substitution at the position corresponding to D10 in SEQ ID NO: 38 comprises an alanine substitution, and wherein the amino acid substitution at the position corresponding to H840 in SEQ ID NO: 48 comprises an alanine substitution.

6 . The fusion protein of claim 1 , wherein the class II type II CRISPR nuclease has no nuclease activity and is capable of interacting with a guide RNA.

7 . The fusion protein of claim 1 , wherein the Spo11 protein comprises a polypeptide sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48.

8 . The fusion protein of claim 7 , wherein the polypeptide sequence comprises an amino acid substitution at a position corresponding to Y135 in SEQ ID NO: 1.

9 . The fusion protein of claim 8 , wherein the amino acid substitution at the position corresponding to Y135 in SEQ ID NO: 1 comprises a phenylalanine substitution.

10 . The fusion protein of claim 1 , wherein the Spo11 protein has no nuclease activity.

11 . The fusion protein of claim 1 , wherein the Spo11 protein is from Capsicum baccatum.

12 . A nucleic acid encoding the fusion protein of claim 1 .

13 . An expression cassette or vector comprising the nucleic acid of claim 12 operably linked to a transcriptional promoter allowing expression of the fusion protein.

14 . The expression cassette or vector of claim 13 , wherein the fusion protein is expressed during meiosis.

15 . A non-human host cell comprising the fusion protein of claim 1 or a nucleic acid encoding the fusion protein.

16 . The non-human host cell of claim 15 , wherein the host cell is a plant cell, a yeast cell or a fungal cell.

17 . A process for inducing targeted meiotic recombination(s) in a eukaryotic cell, comprising:

expressing in the eukaryotic cell:

a) the fusion protein of claim 1 ; and

b) one or more guide RNAs or one or more nucleic acids encoding the guide RNAs, wherein each of the one or more guide RNAs comprises (i) a nuclease binding RNA structure associated with a class II type II CRISPR system, and (ii) a sequence complementary to a targeted chromosomal region.

18 . The process of claim 17 , wherein the eukaryotic cell is a yeast cell.

19 . The process of claim 17 , wherein the eukaryotic cell is a plant cell.

20 . The process of claim 17 , wherein the class II type II CRISPR nuclease of the fusion protein is a Cas9 nuclease.

21 . The process of claim 17 , wherein the class II type II CRISPR nuclease of the fusion protein comprises a polypeptide sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43.

22 . The process of claim 21 , wherein the polypeptide sequence comprises an amino acid substitution at a position corresponding to D10 in SEQ ID NO: 38 and/or an amino acid substitution at a position corresponding to H840 in SEQ ID NO: 38.

23 . The process of claim 22 , wherein the amino acid substitution at the position corresponding to D10 in SEQ ID NO: 38 comprises an alanine substitution, and wherein the amino acid substitution at the position corresponding to H840 in SEQ ID NO: 48 comprises an alanine substitution.

24 . The process of claim 17 , wherein the Spo11 protein of the fusion protein comprises a polypeptide sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48.

25 . The process of claim 24 , wherein the polypeptide sequence comprises an amino acid substitution at a position corresponding to Y135 in SEQ ID NO: 1.

26 . The process of claim 25 , wherein the amino acid substitution at the position corresponding to Y135 in SEQ ID NO: 1 comprises a phenylalanine substitution.

27 . The process of claim 17 , wherein the Spo11 protein is from Capsicum baccatum.

28 . A process for generating variants of a eukaryotic organism, comprising:

expressing in a cell of the eukaryotic organism:

a) the fusion protein of claim 1 ; and

b) one or more guide RNAs or one or more nucleic acids encoding the guide RNAs, wherein each of the one or more guide RNAs comprises (i) a nuclease binding RNA structure associated with a class II type II CRISPR system, and (ii) a sequence complementary to a targeted chromosomal region;

obtaining cell(s) having the desired recombination(s) in the targeted chromosomal region(s); and

generating a variant of the organism from the recombinant cell(s).

29 . A process for identifying or locating genetic information encoding a trait of interest in a eukaryotic cell genome, comprising:

expressing in the eukaryotic cell:

a) the fusion protein of claim 1 ; and

b) one or more guide RNAs or one or more nucleic acids encoding the guide RNAs, wherein each of the one or more guide RNAs comprises (i) a nuclease binding RNA structure associated with a class II type II CRISPR system, and (ii) a sequence complementary to a targeted chromosomal region;

obtaining cell(s) having the desired recombination(s) in the targeted chromosomal region(s); and

analysis of the genotypes and phenotypes of the recombinant cell(s) in order to identify or locate the genetic information encoding a trait of interest.

30 . The process of claim 29 , wherein the trait of interest is a quantitative trait of interest (QTL).